Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
KRYS

KRYS - Krystal Biotech Inc Stock Price, Fair Value and News

177.88USD-4.84 (-2.65%)Market Closed

Market Summary

KRYS
USD177.88-4.84
Market Closed
-2.65%

KRYS Alerts

  • 3 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

KRYS Stock Price

View Fullscreen

KRYS RSI Chart

KRYS Valuation

Market Cap

5.1B

Price/Earnings (Trailing)

88.87

Price/Sales (Trailing)

100.2

EV/EBITDA

259.34

Price/Free Cashflow

-93.32

KRYS Price/Sales (Trailing)

KRYS Profitability

EBT Margin

25.44%

Return on Equity

7.15%

Return on Assets

6.7%

Free Cashflow Yield

-1.07%

KRYS Fundamentals

KRYS Revenue

Revenue (TTM)

50.7M

Rev. Growth (Yr)

957.49%

Rev. Growth (Qtr)

7.37%

KRYS Earnings

Earnings (TTM)

57.2M

Earnings Growth (Yr)

102.06%

Earnings Growth (Qtr)

-89.28%

Breaking Down KRYS Revenue

Last 7 days

8.2%

Last 30 days

9%

Last 90 days

2.8%

Trailing 12 Months

42.6%

How does KRYS drawdown profile look like?

KRYS Financial Health

Current Ratio

12.66

KRYS Investor Care

Shares Dilution (1Y)

10.69%

Diluted EPS (TTM)

2.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202300050.7M
20180000

Tracking the Latest Insider Buys and Sells of Krystal Biotech Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 11, 2024
krishnan suma
sold
-4,393,900
175
-25,000
president, r&d
Jun 11, 2024
krishnan suma
sold
-4,394,160
175
-25,000
president, r&d
Jun 11, 2024
krishnan krish s
sold
-4,394,160
175
-25,000
president and ceo
Jun 11, 2024
krishnan krish s
sold
-4,393,900
175
-25,000
president and ceo
May 20, 2024
gangolli julian s
acquired
455,000
22.75
20,000
-
May 20, 2024
gangolli julian s
sold
-3,282,690
164
-20,000
-
Mar 11, 2024
krishnan suma
sold
-4,274,040
170
-25,000
president, r&d
Mar 11, 2024
krishnan suma
sold
-4,273,680
170
-25,000
president, r&d
Mar 11, 2024
krishnan krish s
sold
-4,273,680
170
-25,000
president and ceo
Mar 11, 2024
krishnan krish s
sold
-4,274,040
170
-25,000
president and ceo

1–10 of 50

Which funds bought or sold KRYS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
new
-
2,143
2,143
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
743,000
2,713,000
-%
May 24, 2024
Cetera Investment Advisers
new
-
201,951
201,951
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
unchanged
-
107,740
355,860
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
67.63
568,032
972,032
0.12%
May 20, 2024
Virtu Financial LLC
new
-
640,000
640,000
0.05%
May 16, 2024
JANE STREET GROUP, LLC
added
85.2
10,400,400
16,680,000
-%
May 16, 2024
CASTLEARK MANAGEMENT LLC
reduced
-11.84
1,061,220
5,074,560
0.21%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.61
867,632
3,320,170
-%
May 16, 2024
COMERICA BANK
reduced
-20.1
3,732
28,987
-%

1–10 of 37

Are Funds Buying or Selling KRYS?

Are funds buying KRYS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own KRYS
No. of Funds

Unveiling Krystal Biotech Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
avoro capital advisors llc
9.1%
2,565,555
SC 13G/A
Feb 14, 2024
redmile group, llc
6.1%
1,733,189
SC 13G/A
Feb 13, 2024
vanguard group inc
8.64%
2,435,774
SC 13G
Feb 12, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 29, 2024
blackrock inc.
6.4%
1,809,377
SC 13G/A
May 10, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2023
avoro capital advisors llc
5.5%
1,410,000
SC 13G
Feb 14, 2023
redmile group, llc
7.4%
1,896,645
SC 13G/A
Feb 14, 2023
point72 asset management, l.p.
2.2%
556,252
SC 13G/A

Recent SEC filings of Krystal Biotech Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
144
Notice of Insider Sale Intent
Jun 11, 2024
144
Notice of Insider Sale Intent
May 22, 2024
4
Insider Trading
May 21, 2024
8-K
Current Report
May 20, 2024
144
Notice of Insider Sale Intent
May 08, 2024
8-K
Current Report
May 06, 2024
8-K
Current Report
May 06, 2024
10-Q
Quarterly Report

Peers (Alternatives to Krystal Biotech Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Krystal Biotech Inc News

Latest updates
MarketBeat32 hours ago
Defense World12 Jun 202410:59 am
Investing.com India12 Jun 202401:40 am
Yahoo Finance23 May 202407:00 am

Krystal Biotech Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12018Q32018Q2
Revenue7.4%45,250,00042,143,0008,556,0006,417,5004,279,0002,140,5002,000
Operating Expenses33.1%51,934,00039,005,50034,549,00038,048,00048,823,0002,972,0002,449,000
  S&GA Expenses5.2%26,058,00024,764,50023,697,00025,904,00024,035,0001,058,000924,000
  R&D Expenses-3.6%10,957,00011,370,00010,629,00012,144,00012,288,0001,914,0001,525,000
EBITDA Margin1.7%0.360.35-----
EBT Margin0%0.250.25-----
Net Income-89.3%932,0008,692,00080,747,000-33,210,000-45,297,000-2,755,000-2,276,000
Net Income Margin422.9%1.130.22-----
Free Cashflow261.1%14,628,000-9,079,000-23,007,000-36,980,000-31,537,000--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets4.3%853818790684532558576601617626451444443311311318205209214205116
  Current Assets2.4%602588582484355384398429438442346370406275288299188196204196108
    Cash Equivalents0.2%35935837327614116218621926934128733040226828229218018819518798.00
  Inventory58.0%11.007.005.00------------------
  Net PPE-0.7%16016116416416316215815113711279.0045.0034.0031.0018.0013.0010.008.007.006.004.00
Liabilities36.1%54.0040.0034.0031.0042.0036.0036.0042.0068.0033.0043.0025.0012.0019.0010.008.007.006.007.007.006.00
  Current Liabilities43.8%48.0033.0028.0024.0035.0029.0028.0034.0060.0026.0036.0018.009.0015.007.006.004.003.004.004.003.00
Shareholder's Equity2.6%799779756653490522541559549594408419431292302310198203208198109
  Retained Earnings0.3%-268-269-278-359-326-280-248-218-190-140-118-103-87.03-71.21-60.83-51.22-44.39-39.05-33.69-29.42-24.07
  Additional Paid-In Capital2.0%1,0681,0481,0351,013816804791780741735527522518363363361243242241228134
Shares Outstanding1.0%29.0028.0028.0028.0026.0026.0025.0025.0025.0022.0022.0022.00---------
Float----2,800---1,400---1,200---595---454-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations319.7%15,888-7,232-21,226-34,190-26,156-22,329-19,688-43,059-15,493-20,900-7,255-10,129-9,654-8,024-6,778-5,054-6,227-7,000-4,266-4,209-3,215
  Share Based Compensation-5.6%9,2999,8538,31211,33110,4379,5529,0598,1896,4305,1453,6664,1952,3135701,356807539323278325313
Cashflow From Investing-155.7%-25,980-10,160105,192-15,9573,563-5,208-14,743-38,224-55,908-126,540-37,166-62,317-747-6,217-2,697-962-1,305-591-682-1,236-2,482
Cashflow From Financing304.1%10,5832,61913,388185,2691,4743,0692,12030,700-542202,0721,508-199144,304141166117,46924329913,16794,01940.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

KRYS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]Product [Member]Product [Member]
Product revenue, net$ 45,250$ 0
Expenses  
Cost, Product and Service [Extensible Enumeration]Product [Member]Product [Member]
Cost of goods sold$ 2,419$ 0
Research and development10,95712,288
Selling, general, and administrative26,05824,035
Litigation settlement12,50012,500
Total operating expenses51,93448,823
Loss from operations(6,684)(48,823)
Other income  
Interest and other income, net7,6163,526
Net income (loss)932(45,297)
Unrealized (loss) gain on available-for-sale securities and other(937)[1]574
Comprehensive loss$ (5)$ (44,723)
Net income (loss) per common share: basic (in dollars per share)$ 0.03$ (1.76)
Net income (loss) per common share: diluted (in dollars per share)$ 0.03$ (1.76)
Weighted-average common shares outstanding: basic (in shares)28,295,00025,712,000
Weighted-average common shares outstanding: diluted (in shares)29,291,00025,712,000
[1]Includes foreign currency translation losses of $62 thousand and $35 thousand for the three months ended March 31, 2024 and 2023, respectively.

KRYS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 359,006$ 358,328
Short-term investments179,253173,850
Accounts receivable, net46,46742,040
Inventory11,0376,985
Prepaid expenses and other current assets6,4856,706
Total current assets602,248587,909
Property and equipment, net160,011161,202
Long-term investments83,99661,954
Right-of-use assets6,8457,027
Other non-current assets196263
Total assets853,296818,355
Current liabilities  
Accounts payable5,3594,132
Current portion of lease liability1,4301,474
Accrued rebates11,2895,977
Accrued expenses and other current liabilities29,51121,511
Total current liabilities47,58933,094
Lease liability6,4656,620
Total liabilities54,05439,714
Commitments and contingencies (see note 7)
Stockholders' equity  
Common stock; $0.00001 par value; 80,000 shares authorized as of March 31, 2024 and December 31, 2023; 28,528 and 28,237 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.00
Additional paid-in capital1,068,4361,047,830
Accumulated other comprehensive (loss) gain(299)638
Accumulated deficit(268,895)(269,827)
Total stockholders’ equity799,242778,641
Total liabilities and stockholders’ equity$ 853,296$ 818,355
KRYS
Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
 CEO
 WEBSITEkrystalbio.com
 INDUSTRYBiotechnology
 EMPLOYEES210

Krystal Biotech Inc Frequently Asked Questions


What is the ticker symbol for Krystal Biotech Inc? What does KRYS stand for in stocks?

KRYS is the stock ticker symbol of Krystal Biotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Krystal Biotech Inc (KRYS)?

As of Fri Jun 14 2024, market cap of Krystal Biotech Inc is 5.08 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KRYS stock?

You can check KRYS's fair value in chart for subscribers.

What is the fair value of KRYS stock?

You can check KRYS's fair value in chart for subscribers. The fair value of Krystal Biotech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Krystal Biotech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KRYS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Krystal Biotech Inc a good stock to buy?

The fair value guage provides a quick view whether KRYS is over valued or under valued. Whether Krystal Biotech Inc is cheap or expensive depends on the assumptions which impact Krystal Biotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KRYS.

What is Krystal Biotech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, KRYS's PE ratio (Price to Earnings) is 88.87 and Price to Sales (PS) ratio is 100.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KRYS PE ratio will change depending on the future growth rate expectations of investors.